"A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors"

2006

"Trattamento con Fattore VIIA Ricombinante (rFVIIA) ad alte dosi in emofilici con inibitore: Studio randomizzato crossover."

2005

Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2…

2009

AbstractData from the Italian Hemophilia Centres were collected to perform a retrospective survey of joint arthroplasty in patients with severe hemophilia. Twenty-nine of 49 hemophilia centers reported that 328 of the 347 operations were carried out in 253 patients with severe hemophilia A (HA) and 19 in 15 patients with severe hemophilia B (HB). When results were normalized to the whole Italian hemophilia population (1770 severe HA and 319 severe HB), patients with HA had a 3-fold higher risk of undergoing joint arthroplasty (odds ratio [OR], 3.38; 95% confidence interval [CI], 1.97-5.77; P < .001). These results were confirmed after adjustment for age, HIV, hepatitis C virus (HCV), and…

Immune Tolerance Induction (ITI) with FVIII/VWF concentrate in Italian haemophiliacs with previous unsuccessful ITI and/or negative predictors of ITI…

2008

"Prophylaxis with Factor VIII Protects Children with Hemophilia a from inhibitor Development."

2005

"A randomized crossover study of high- and standard-dose recombinant factor VIIa for home treatment of hemarthroses in hemophiliacs with inhibitors."

2006

Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis

2008

Immune Tolerance Induction (ITI) in patients wuth hemophilia A and inhibitors: the Italian Retrospective-Prospective Registry - the PROFIT Study .

2008

Demographic and clinical data in acquired hemophilia A

2012

Summary.  Background:  Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies against coagulation factor VIII and characterized by spontaneous hemorrhage in patients with no previous family or personal history of bleeding. Although data on several AHA cohorts have been collected, limited information is available on the optimal management of AHA. Objectives:  The European Acquired Hemophilia Registry (EACH2) was established to generate a prospective, large-scale, pan-European database on demographics, diagnosis, underlying disorders, bleeding characteristics, treatment and outcome of AHA patients. Results:  Five hundred and one (266 male, 235 female) patients from …